Global Dilated Cardiomyopathy Epidemiology Forecast to 2030 - ResearchAndMarkets.com

The "Dilated Cardiomyopathy (DCM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted Dilated Cardiomyopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Cardiomyopathy is a general term that refers to the disorders of the cardiac muscle that cause mechanical or electrical dysfunction resulting in dilated, hypertrophic or restrictive pathophysiology. In Cardiomyopathy, the walls of the heart chambers become stretched, thickened or stiff; this affects the heart's ability to pump blood around the body.

Dilated Cardiomyopathy (DCM) is characterized by left ventricular or biventricular dilation and impaired contraction, which lessens the heart effectiveness at pumping blood that is not explained by abnormal loading conditions like hypertension, valvular heart disease or coronary artery disease. It is a nonischemic heart muscle disease with structural and functional myocardial abnormalities.

The World Health Organization (WHO) defines DCM as a severe cardiac disorder in which structural or functional abnormalities of the heart muscle can lead to substantial morbidity and mortality owing to complications such as heart failure and arrhythmia.

Familial dilated cardiomyopathy is a genetic form of heart disease affecting around 30% cases of DCM. The most common genes involved in DCM are LMNA44, MYH7, TNNT2, TTN46, RBM20, and BAG3. TTN truncating mutations are a common cause of DCM, occurring in 15-20% of familial cases of DCM

Report Highlights

• 11-Year Forecast of Dilated Cardiomyopathy epidemiology
• 7MM Coverage
• Total Prevalent Cases of Dilated Cardiomyopathy
• Total Diagnosed Cases of Dilated Cardiomyopathy
• Diagnosed cases according to segmentation: Familial and Non-familial, Gender Specific
• Treated cases of Dilated Cardiomyopathy

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dilated Cardiomyopathy?
• What are the key findings pertaining to the Dilated Cardiomyopathy epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
• What would be the total number of patients of Dilated Cardiomyopathy across the 7MM during the study period (2017-2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Dilated Cardiomyopathy?
• What proportion of Dilated Cardiomyopathy patients are suffering from familial and non-familial DCM?

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the global Dilated Cardiomyopathy market
• Quantify patient populations in the global Dilated Cardiomyopathy market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Dilated Cardiomyopathy therapeutics in each of the markets covered
• Understand the magnitude of Dilated Cardiomyopathy population by its severity
• The Dilated Cardiomyopathy epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Dilated Cardiomyopathy Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Topics Covered:

1. Key Insights

2. Executive Summary of Dilated Cardiomyopathy

3. SWOT Analysis of Dilated Cardiomyopathy

4. Dilated Cardiomyopathy: Market Overview at a Glance

5. Dilated Cardiomyopathy: Disease Background and Overview

5.1. Introduction

5.1.1. Classification Systems and Nomenclature of Cardiomyopathies

5.1.2. Dilated Cardiomyopathy (DCM)

5.1.3. Symptoms of DCM

5.1.4. Causes of DCM

5.1.5. Genetics of DCM

5.1.6. Pathophysiology of DCM

6. Diagnosis

6.1. Diagnosis of DCM

6.1.1. Imaging Techniques

6.1.2. Endomyocardial Biopsy

6.1.3. Non-invasive Arrhythmia Monitoring

6.1.4. Genetic Testing

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Prevalent Population of Dilated Cardiomyopathy in the 7MM

7.3.2. Total Diagnosed Population of Dilated Cardiomyopathy in the 7MM

7.3.3. Familial and non-familial cases of Dilated Cardiomyopathy in the 7MM

7.3.4. Total treated cases of Dilated Cardiomyopathy in the 7MM

8. The United States Epidemiology

9. EU-5 Epidemiology

10. Japan Epidemiology

11. Appendix

11.1. Bibliography

11.2. Report Methodology

12. The Publisher's Capabilities

13. Disclaimer

14. About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/m4dekf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005633/en/